SEARCH
ProFound AI
Discover the ProFound impact of artificial intelligence for digital breast tomosynthesis
FDA Cleared, CE Mark, Health Canada Licensed
PowerLook Density Assessment
Automated Breast Density Assessment for Accurate and Objective Breast Density Scoring
<
>
About iCAD
iCAD is a global leader in advanced breast cancer detection solutions built on artificial intelligence that empower radiologists to find cancers earlier while improving reading workflow. Our Breast Health Solutions suite delivers powerful detection and workflow solutions for 2D and 3D mammography.
From the Newsroom
May 7, 2019
iCAD Reports First Quarter 2019 Financial Result
May 6, 2019
iCAD Appoints R. Scott Areglado As Chief Financial Officer
May 1, 2019
iCAD to Report First Quarter 2019 Financial Results on Tuesday, May 7
» View all news »
Podcast: The AI Solution That Saves Lives
Listen to the Healthcare Weekly podcast interview with iCAD Chairman & CEO, Mike Klein, to learn about the history of iCAD, ProFound AI, new features and functionalities iCAD plans to release later this year and the future of AI in healthcare.
Healthcare Weekly:
At the Forefront of Healthcare Innovation in Podcasts.
iNFORMED - Blog
Inform, connect and engage. We invite you to engage with us to participate on the topic of cancer detection solutions, patient stories, clinical expertise.
Customer Spotlight
Southwest Diagnostic Imaging Center Uses Artificial Intelligence to Optimize Breast Tomosynthesis Interpretations
Clinical Feature
Improving reading time of digital breast tomosynthesis with concurrent computer aided detection.
Supporting cancer detection for 3,500+ healthcare facilities worldwide
Speak to a specialist today at 1.866.280.2239
CONNECT
© 2018, iCAD Inc. All rights reserved. iCAD, the iCAD logo,, PowerLook, ProFound AI, ProFound, Xoft, the Xoft logo, Axxent, Electronic Brachytherapy System and eBx are trademarks of iCAD, Inc. Reproduction of any of the material contained herein in any format or media without the express written permission of iCAD, Inc. is prohibited.
